Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.

Autor: Goteti K; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., French J; Metrum Research Group, Tariffville, Connecticut, USA., Garcia R; Metrum Research Group, Tariffville, Connecticut, USA., Li Y; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., Casset-Semanaz F; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., Aydemir A; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., Townsend R; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., Mateo CV; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., Studham M; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., Guenther O; Merck KGaA, Darmstadt, Germany., Kao A; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., Gastonguay M; Metrum Research Group, Tariffville, Connecticut, USA., Girard P; Merck Institute of Pharmacometrics, Lausanne, Switzerland., Benincosa L; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA., Venkatakrishnan K; EMD Serono Research and Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt Germany), Billerica, Massachusetts, USA.

Publikováno v: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Feb; Vol. 12 (2), pp. 180-195. Date of Electronic Publication: 2022 Nov 29.

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study

Autor: Freedman MS, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM, Casset Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L., COMI , GIANCARLO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10495::4276dbb64f8da4b72178d2bfa4bd79a9

A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis.

Autor: Svecova D; Faculty of Medicine of Comenius University, Bratislava, Slovakia., Lubell MW; EMD Serono Research and Development Institute, Billerica, Massachusetts., Casset-Semanaz F; EMD Serono Research and Development Institute, Billerica, Massachusetts., Mackenzie H; EMD Serono Research and Development Institute, Billerica, Massachusetts., Grenningloh R; EMD Serono Research and Development Institute, Billerica, Massachusetts. Electronic address: roland.grenningloh@emdserono.com., Krueger JG; Rockefeller University, New York, New York.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2019 Jul; Vol. 81 (1), pp. 196-203. Date of Electronic Publication: 2019 Mar 27.

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Autor: Giovannoni, G., Barbarash, O., Casset-Semanaz, F., King, J., Metz, L., Pardo, G., Simsarian, J., Sørensen, P. S., Stubinski, B.

Publikováno v: Multiple Sclerosis (13524585); Feb2009, Vol. 15 Issue 2, p219-228, 10p, 1 Diagram, 3 Charts, 2 Graphs

纳米抗体在自身免疫性疾病中的应用.

Autor: 敖正宏¹ 1203041929@qq.com, 王 玥¹, 梅雅贤¹, 罗文新¹ wxluo@xmu.edu.cn

Publikováno v: Chinese Journal of Immunology. Jan2024, Vol. 40 Issue 1, p178-184. 7p.